OBJECTIVE: In the present study, we compared the effects of treatment with the novel soluble epoxide hydrolase (sEH) inhibitor (c-AUCB) with those of the AT1 receptor antagonist losartan on blood pressure (BP), autoregulation of renal blood flow (RBF) and on glomerular filtration rate (GFR) and the pressure-natriuresis relationship in response to stepwise reduction in renal arterial pressure (RAP) in Cyp1a1-Ren-2 transgenic rats. METHODS: Hypertension was induced in Cyp1a1-Ren-2 rats through dietary administration for 11 days of the natural xenobiotic indole-3-carbinol (I3C) which activates the renin gene. Treatment with c-AUCB and losartan was started 48 h before initiating administration of the diet containing I3C. Rats were prepared for renal functional studies to evaluate in-vivo renal autoregulatory efficiency when RAP was gradually decreased by an aortic clamp. RESULTS: I3C administration resulted in the development of severe hypertension which was associated with markedly lower basal RBF and GFR and substantially impaired autoregulatory efficiency as well as a suppression of the pressure-natriuresis relationship when compared with noninduced rats. Treatment with c-AUCB significantly decreased BP, improved autoregulatory efficiency of RBF and GFR and the slope of pressure-natriuresis relationship. Treatment with losartan completely prevented the impaired autoregulation and pressure-natriuresis relationship as well as the development of hypertension in I3C-induced rats. CONCLUSION: Our present findings indicate that chronic treatment with the sEH inhibitor c-AUCB substantially attenuates the development of malignant hypertension in I3C-induced rats likely via improvement of the renal autoregulatory efficiency and the pressure-natriuresis relationship.

Center of Cardiovascular Research Prague Czech Republic

Department for Experimental Medicine Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Entomology and UCD Cancer Center University of California Davis Davis California USA

Department of Nephrology 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Pathology 3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Pharmacology and Toxicology Medical College of Wisconsin Wisconsin USA

Department of Physiology 2nd Faculty of Medicine Charles University Prague Czech Republic

Section of Nephrology Medical Policlinic Department of Medicine University Bonn Bonn Germany

000      

00000naa a2200000 a 4500

001      

bmc12022390

003      

CZ-PrNML

005      

20190430165304.0

007      

ta

008      

120806s2011 xxk f 000 0#eng||

009      

AR

024    7_

$a 10.1097/HJH.0b013e328349062f $2 doi

035    __

$a (PubMed)21720266

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Honetschlägerová, Zuzana $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center of Cardiovascular Research, Prague, Czech Republic

245    10

$a Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats / $c Zuzana Honetschlägerová, Alexandra Sporková, Libor Kopkan, Zuzana Husková, Sung H. Hwang, Bruce D. Hammock, John D. Imig, Herbert J. Kramer, Petr Kujal, Zdenka Vernerová, Věra Č. Chábová, Vladimír Tesař, Luděk Červenka

520    9_

$a OBJECTIVE: In the present study, we compared the effects of treatment with the novel soluble epoxide hydrolase (sEH) inhibitor (c-AUCB) with those of the AT1 receptor antagonist losartan on blood pressure (BP), autoregulation of renal blood flow (RBF) and on glomerular filtration rate (GFR) and the pressure-natriuresis relationship in response to stepwise reduction in renal arterial pressure (RAP) in Cyp1a1-Ren-2 transgenic rats. METHODS: Hypertension was induced in Cyp1a1-Ren-2 rats through dietary administration for 11 days of the natural xenobiotic indole-3-carbinol (I3C) which activates the renin gene. Treatment with c-AUCB and losartan was started 48 h before initiating administration of the diet containing I3C. Rats were prepared for renal functional studies to evaluate in-vivo renal autoregulatory efficiency when RAP was gradually decreased by an aortic clamp. RESULTS: I3C administration resulted in the development of severe hypertension which was associated with markedly lower basal RBF and GFR and substantially impaired autoregulatory efficiency as well as a suppression of the pressure-natriuresis relationship when compared with noninduced rats. Treatment with c-AUCB significantly decreased BP, improved autoregulatory efficiency of RBF and GFR and the slope of pressure-natriuresis relationship. Treatment with losartan completely prevented the impaired autoregulation and pressure-natriuresis relationship as well as the development of hypertension in I3C-induced rats. CONCLUSION: Our present findings indicate that chronic treatment with the sEH inhibitor c-AUCB substantially attenuates the development of malignant hypertension in I3C-induced rats likely via improvement of the renal autoregulatory efficiency and the pressure-natriuresis relationship.

650    _2

$a blokátory receptoru 1 pro angiotenzin II $x farmakologie $7 D047228

650    _2

$a zvířata $7 D000818

650    _2

$a krevní tlak $x účinky léků $x fyziologie $7 D001794

650    _2

$a cytochrom P-450 CYP1A1 $x genetika $7 D019363

650    _2

$a modely nemocí na zvířatech $7 D004195

650    _2

$a inhibitory enzymů $x farmakologie $7 D004791

650    _2

$a epoxid hydrolasy $x antagonisté a inhibitory $7 D004851

650    _2

$a hodnoty glomerulární filtrace $x účinky léků $x fyziologie $7 D005919

650    _2

$a hypertenze maligní $x chemicky indukované $x patofyziologie $x prevence a kontrola $7 D006974

650    _2

$a indoly $x škodlivé účinky $7 D007211

650    _2

$a ledviny $x krevní zásobení $x patologie $x patofyziologie $7 D007668

650    _2

$a nemoci ledvin $x patofyziologie $x prevence a kontrola $7 D007674

650    _2

$a losartan $x farmakologie $7 D019808

650    _2

$a natriuréza $x účinky léků $x fyziologie $7 D009318

650    _2

$a krysa rodu Rattus $7 D051381

650    _2

$a potkani transgenní $7 D055647

650    _2

$a regionální krevní průtok $x účinky léků $x fyziologie $7 D012039

650    _2

$a renin $x genetika $7 D012083

655    _2

$a srovnávací studie $7 D003160

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Sporková, Alexandra $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center of Cardiovascular Research, Prague, Czech Republic

700    1_

$a Kopkan, Libor $7 xx0107287 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center of Cardiovascular Research, Prague, Czech Republic

700    1_

$a Husková, Zuzana, $d 1978- $7 xx0074206 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center of Cardiovascular Research, Prague, Czech Republic

700    1_

$a Hwang, Sung H. $u Department of Entomology and UCD Cancer Center, University of California, Davis, Davis, California, USA

700    1_

$a Hammock, Bruce D. $u Department of Entomology and UCD Cancer Center, University of California, Davis, Davis, California, USA

700    1_

$a Imig, John D. $u Department of Pharmacology and Toxicology, Medical College of Wisconsin, Wisconsin, USA

700    1_

$a Kramer, Herbert J. $u Section of Nephrology, Medical Policlinic, Department of Medicine, University Bonn, Bonn, Germany

700    1#

$a Kujal, Petr $7 xx0244311 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Pathology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic

700    1_

$a Vernerová, Zdenka, $d 1960-2020 $7 jo2002104672 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Pathology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic

700    1_

$a Čertíková-Chábová, Věra $7 xx0095872 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

700    1_

$a Tesař, Vladimír, $d 1957- $7 jn20000402349 $u Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

700    1_

$a Červenka, Luděk, $d 1967- $7 xx0037105 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Physiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic

773    0_

$w MED00002723 $t Journal of hypertension $x 1473-5598 $g Roč. 29, č. 8 (2011), s. 1590-1601

856    41

$u https://pubmed.ncbi.nlm.nih.gov/21720266 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y m $z 0

990    __

$a 20120806 $b ABA008

991    __

$a 20190430165349 $b ABA008

999    __

$a ok $b bmc $g 944303 $s 779687

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2011 $b 29 $c 8 $d 1590-1601 $i 1473-5598 $m Journal of hypertension $n J Hypertens $x MED00002723

GRA    __

$a NS9699 $p MZ0

GRA    __

$a NS10500 $p MZ0

GRA    __

$a NS9703 $p MZ0

GRA    __

$a NS10499 $p MZ0

LZP    __

$a Pubmed-20120806/12/01